Sanofi (SNY)

Market Cap	105.41B -20.4%
Revenue (ttm)	54.60B +4.8%
Net Income	8.71B +19.9%
EPS	3.58 +23.0%
Shares Out	1.20B
PE Ratio	12.10
Forward PE	8.83
Dividend	$1.76 (4.05%)
Ex-Dividend Date	May 4, 2026

Volume	3,525,655
Open	43.41
Previous Close	44.73
Day's Range	43.36 - 44.20
52-Week Range	42.28 - 52.68
Beta	0.28
Analysts	Buy
Price Target	55.90 (+28.3%)
Earnings Date	Jul 30, 2026

About SNY

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for onc...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1994
• Employees: 74,846
• Stock Exchange: NASDAQ
• Ticker Symbol: SNY
• Website: https://www.sanofi.com

Financial Performance

In 2025, Sanofi's revenue was 46.72 billion, an increase of 5.49% compared to the previous year's 44.29 billion. Earnings were 7.81 billion, an increase of 40.52%.

Financial numbers in EUR

Analyst Summary

According to 10 analysts, the average rating for SNY stock is "Buy." The 12-month stock price target is $55.9, which is an increase of 28.30% from the latest price.

Price Target

$55.9

(28.30% upside)

Analyst Consensus: Buy